
| Guidelines for good clinical practice (GCP) for trials on pharmaceutical products (WHO Technical Report Series, No. 850, 1995, Annex 3) (WHO, 1995, 36 p.) |
| 10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS |
![]() |
|
1 See also sections 5 and 6.
The sponsor is responsible for:
· Supplying the investigational and, when appropriate, comparator product(s), prepared in accordance with principles of Good Manufacturing Practice. The products should be fully characterized, properly coded, and suitably packaged in such a way as to provide protection against deterioration during transport and storage at intermediate destinations; appropriate investigational labelling should be affixed (see Section 10.2).· Ensuring that the package of investigational product(s) is of a size suitable for the trial and adequate for the trial subjects.
· Keeping sufficient samples from each batch used in the trial as a reference for control tests and validation of data, as required in national regulations.
· Providing information about the expiry date (month/year) or retest date information in a manner understandable to all staff involved in the trial.
During the visits to the clinical trial site, the monitor should check:
· That all study products for the trial are used exclusively within the limits defined by the protocol.· That inventory records of study products are in order and that there are sufficient supplies.
· That the expiry dates are not likely to be, or have not been, exceeded.
· That the storage conditions for study products are adequate.
· Procedures for and records of returned and/or unused study products.